<DOC>
	<DOCNO>NCT01728727</DOCNO>
	<brief_summary>HBV relate Liver disease common medical problem China . An estimated 7.18 % Chinese ( 93 million ) infect hepatitis B , HBV- relate hepatitis develop liver cirrhosis . Liver transplantation available life save treatment patient end stage liver disease . However , lack donor , surgical complication , rejection , high cost serious problem . Mesenchymal stem cell ( MSCs ) posse plasticity potential differentiate hepatocyte ; Thus , MSCs hold great hope therapeutic application . Human umbilical cord-derived MSCs ( hUC-MSCs ) exhibit beneficial immunogenic profile great overall immunosuppressive potential age bone marrow-derived MSCs . Like MSCs derive bone marrow , hUC-MSCs also use treat rat liver fibrosis improve glucose homeostasis rat liver cirrhosis . In study , patient HBV-related liver cirrhosis undergo administration hUC-MSCs via hepatic artery evaluate safety efficacy hUC-MSC treatment patient .</brief_summary>
	<brief_title>Safety Efficacy Human Umbilical Cord Derived Mesenchymal Stem Cells Treatment HBV-related Liver Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<criteria>1 . Aged 1865 year 2 . HBVrelated liver cirrhosis 3 . ChildPugh score 915 4 . Written consent 1 . Hepatocellular carcinoma malignancy 2 . Severe problem vital organ ( e.g.the heart , renal lung ) 3 . Pregnant lactate woman 4 . Severe bacteria infection 5 . Anticipated difficulty followup observation 6 . Other candidate judge applicable study doctor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>liver cirrhosis</keyword>
	<keyword>end stage liver disease</keyword>
	<keyword>umbilical cord</keyword>
	<keyword>mesenchymal stem cell</keyword>
	<keyword>HBV</keyword>
</DOC>